(NASDAQ: LXRX) Lexicon Pharmaceuticals's forecast annual revenue growth rate of 16.06% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.84%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.9%.
Lexicon Pharmaceuticals's revenue in 2026 is $41,469,000.On average, 7 Wall Street analysts forecast LXRX's revenue for 2026 to be $17,222,019,425, with the lowest LXRX revenue forecast at $13,862,157,168, and the highest LXRX revenue forecast at $20,697,125,270. On average, 7 Wall Street analysts forecast LXRX's revenue for 2027 to be $9,037,499,975, with the lowest LXRX revenue forecast at $0, and the highest LXRX revenue forecast at $27,331,418,246.
In 2028, LXRX is forecast to generate $34,446,708,587 in revenue, with the lowest revenue forecast at $2,616,340,892 and the highest revenue forecast at $69,159,500,822.